Popular Pharma Products
 
 
 
AngivasTM
Trimetazidine
Angivas<sup>TM</sup>

Angivas 20 Tablet: Each film coated tablet contains Trimetazidine Hydrochloride BP 20 mg. Angivas MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

Find more about this product

Pharmacology/Description

Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid b-oxidation. This is made possible by selective inhibition of an enzyme of fatty acid b-oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation.

Indication

Trimetazidine is indicated in prophylactic treatment of episodes of angina pectoris and sequelae of infarction, heart failure. Adjuvant symptomatic treatment of vertigo and tinnitus. Adjuvant treatment of the decline in visual acuity and visual field disturbances presumably of vascular origin.

Dosage And Administration

Angivas 20 Tablet: 1 tablet 3 times daily after meals. Angivas MR Tablet: 1 tablet at mealtimes in the morning and evening. Child: Not recommended. For patients with impaired renal function (creatinine clearance between 15 and 90 mL/min), the starting dose is one tablet twice daily respectively in the morning and in the evening.

Side Effects

Gastrointestinal disorders: Gastralgia, dyspepsia, diarrhoea, constipation, nausea, vomiting General disorders: Asthenia Nervous system disorders: Headaches, vertigo, sleep disorders (insomnia, somnolence), aggravation of Parkinsonian symptoms, reversible on the discontinuation of treatment Skin disorders: Rash, pruritus, urticaria, angioedema or Quincke's oedema, AGEP (acute generalized exanthematous pustulosis). The onset of these effects can vary from a few hours to several days. Cardiovascular disorders: Orthostatic hypotension, which may be associated with fainting, vertigo or a fall, especially in elderly subjects on antihypertensive treatment, palpitations, extrasystoles, tachycardia.

Contraindications

This drug should never be used in patients who are hypersensitive to any of its constituents.

Drug Interactions

The clinical studies of Trimetazidine showed no evidence of interactions with other drugs, particularly in elderly patients.

Precautions

This drug is not a curative treatment for angina attacks, nor is it indicated as an initial treatment for unstable angina, or myocardial infarction. It should not be used in the pre-hospital phase or during the first days of hospitalization. In the event of an angina attack, the coronaropathy should be reevaluated and an adaptation of the treatment considered (drug treatment and possibly revascularisation). In patients with renal failure, prescription of Trimetazidine is not recommended if the creatinine clearance is lower than 15 ml/min (in the absence of specific studies). In patients with severe hepatic failure, in the absence of specific studies, prescription of Trimetazidine is not recommended.

Over Dosage

Very limited information is available on Trimetazidine overdose. Treatment should be symptomatic.

Pharmaceutical Precautions

Store in a cool and dry place, protected from light and moisture. Keep all medicines out of the reach of children.

Commercial Pack

Angivas 20 Tablet: Each box contains 5X10 tablets in Alu-Alu blister pack. Angivas MR Tablet: Each box contains 3X10 tablets in Alu-Alu blister pack.